<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Variations Improper activation and inappropriate expression of fibroblast growth factor receptors (<italic>FGFRs</italic>) in cancer suggests that they can act as therapeutic targets. Fibroblast growth factor receptor inhibitors are currently employed in clinical trials of different cancers. Regarding the essence and the importance of the personalized medicine, mainly mirrored by remarkable inter-individual variations in different populations, we aimed to perform a pilot study to address <italic>FGFR1</italic> and <italic>FGFR3</italic> expression levels and their correlation with the clinicopathological features in Iranian patients with bladder cancer (BC). Paired tumor and adjacent non tumor tissue samples along with their clinico-pathological parameters were obtained from 50 cases diagnosed with BC in different stages and grades. The mRNA expressions of <italic>FGFR1</italic> and <italic>FGFR3</italic> in tissue samples were determined by real-time polymerase chain reaction (real-time PCR). The expression levels of <italic>FGFR3</italic> were significantly higher in tumor tissues when compared to adjacent normal tissues (<italic>p</italic> = 0.007), regardless of the stages and grades of the tumor. Over expression was associated with cigarette smoking (<italic>p</italic> = 0.037) and family history for cancer (<italic>p</italic> = 0.004). Decreased expression of <italic>FGFR1</italic> was observed, remarkably evident in high-grade tumors (<italic>p</italic> = 0.047), while over expression was detected in low-grade samples. This pilot study clearly suggests that in Iranian BC patients <italic>FGFR1</italic> and <italic>FGFR3</italic> expression patterns are different, and also highly distinctive with regard to the tumor’s stage and grade. Such particular expression patterns may indicate their special values to be employed for interventional studies aiming targeted therapy. Further studies with a larger sample size are needed to validate our results.</p></abstract>

Variations Improper activation and inappropriate expression of fibroblast growth factor receptors (FGFRs) in cancer suggests that they can act as therapeutic targets. Fibroblast growth factor receptor inhibitors are currently employed in clinical trials of different cancers. Regarding the essence and the importance of the personalized medicine, mainly mirrored by remarkable inter-individual variations in different populations, we aimed to perform a pilot study to address FGFR1 and FGFR3 expression levels and their correlation with the clinicopathological features in Iranian patients with bladder cancer (BC). Paired tumor and adjacent non tumor tissue samples along with their clinico-pathological parameters were obtained from 50 cases diagnosed with BC in different stages and grades. The mRNA expressions of FGFR1 and FGFR3 in tissue samples were determined by real-time polymerase chain reaction (real-time PCR). The expression levels of FGFR3 were significantly higher in tumor tissues when compared to adjacent normal tissues (p = 0.007), regardless of the stages and grades of the tumor. Over expression was associated with cigarette smoking (p = 0.037) and family history for cancer (p = 0.004). Decreased expression of FGFR1 was observed, remarkably evident in high-grade tumors (p = 0.047), while over expression was detected in low-grade samples. This pilot study clearly suggests that in Iranian BC patients FGFR1 and FGFR3 expression patterns are different, and also highly distinctive with regard to the tumor’s stage and grade. Such particular expression patterns may indicate their special values to be employed for interventional studies aiming targeted therapy. Further studies with a larger sample size are needed to validate our results.

Differential expression of FGFRs signaling pathway components in bladder cancer: A step toward personalized medicine

Department of Pathobiology, School of Public Health

Department of Medical Immunology and Genetics, Faculty of Medicine

Balkan Journal of Medical Genetics

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Variations Improper activation and inappropriate expression of fibroblast growth factor receptors (FGFRs) in cancer suggests that they can act as therapeutic...

Differential expression of FGFRs signaling pathway components in bladder cancer: A step toward personalized medicine

Article Category: Original Article

Online veröffentlicht: 29. Dez. 2017

Seitenbereich: 75 - 81

DOI: https://doi.org/10.1515/bjmg-2017-0026

Schlüsselwörter
Bladder cancer (BC), FGFR signaling, Targeted therapy

© 2017 Ousati Ashtiani Z, Tavakkoly-Bazzaz J, Salami SA, Pourmand MR, Mansouri F, Mashahdi R, Pourmand G, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Differential expression of FGFRs signaling pathway components in bladder cancer: A step toward personalized medicine

Article Category: Original Article

Online veröffentlicht: 29. Dez. 2017

Seitenbereich: 75 - 81

DOI: https://doi.org/10.1515/bjmg-2017-0026

SchlüsselwörterBladder cancer (BC), FGFR signaling, Targeted therapy

© 2017 Ousati Ashtiani Z, Tavakkoly-Bazzaz J, Salami SA, Pourmand MR, Mansouri F, Mashahdi R, Pourmand G, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Schlüsselwörter
Bladder cancer (BC), FGFR signaling, Targeted therapy